B-Cell Disorders and Curcumin
Terry Golombick PhD, Dipl, Nutr, Terrence H. Diamond MB BCh, MRCP, FRACP, Arumugam Manoharan MD, FRACP, FRCPA and 1 more
Integrative Cancer Therapies · 2017
doi:10.1177/1534735415622013 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Clinical studies with patients with early hematological malignancies (ie, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia) suggest that early intervention with curcumin, derived from the spice turmeric, may lead to prolonged survival and delay in progressive disease in some of these patients.
Abstract licence: CC BY-NC
Cited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.